Lantheus Takes a Dive into Pharma with Proposed Acquisition
Lantheus Holdings is expanding its presence in the world of radiopharmaceutical diagnostics through a newly-proposed acquisition. On Wednesday, the North Billerica, MA-based company announced it would acquire Progenics Pharmaceuticals, an oncology company developing solutions to find, fight, and follow cancer in an all-stock transaction.
The transaction has been unanimously approved by the Boards of Directors of both companies.
Under the terms of the agreement, Lantheus Holdings will acquire all of the issued and outstanding common shares of Progenics stock at a fixed exchange ratio. Progenics shareholders will receive 0.2...
Source: MDDI - October 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Imaging Source Type: news
Upstate hosts International Conference on Pheo Para
Conference will host what is expected to be the largest single gathering of patients who have battled pheochromocytoma and paraganglioma, a rare condition marked by cancerous tumors. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - June 6, 2019 Category: Universities & Medical Training Source Type: news
CNIO researchers identify a new gene involved in the development of a rare endocrine tumour
(Centro Nacional de Investigaciones Oncol รณ gicas (CNIO)) Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours and also the most hereditary form of all types of cancer. Researchers have for the first time linked mutations in the DLST gene with the development of such tumors. In addition to the importance of this finding for the future therapies, the discovery can broaden the number of families that may benefit from genetic counselling for prevention, detection and monitoring of these cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2019 Category: Cancer & Oncology Source Type: news
Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Can Simple Clinical Factors Predict Metastatic Potential of Neuroendocrine Tumors?
Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
FDA Approves Iobenguane I 131 for Rare Adrenal Gland Tumors
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
FDA approves Progenics' drug for rare tumors
The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2018 Category: Pharmaceuticals Source Type: news
